PFK27 Antibody

Definition and Biological Context of PFK27

PFK27 (Saccharomyces cerevisiae gene) encodes a phosphofructokinase 2 (PFK-2) isoform involved in regulating glycolysis by modulating fructose-2,6-bisphosphate (F2,6BP) levels . Unlike mammalian PFK-2/FBPase-2 bifunctional enzymes, yeast PFK27 primarily functions in F2,6BP synthesis, which activates phosphofructokinase 1 (PFK-1) to enhance glycolytic flux .

Key Functional Domains:

• Walker A/B motifs for ATP binding .

• Catalytic residues (e.g., Lys 174) critical for PFK-2 activity .

• Structural homology to adenylate kinase (AK) .

Table 1: Antibodies Targeting Phosphofructokinase Isoforms

Role in Glycolytic Regulation

• PFK27 deletion reduces F2,6BP production, impairing glycolytic flux in yeast .

• Compensatory upregulation of PFKFB isoforms (e.g., PFKFB1, PFKFB4) occurs under metabolic stress .

Interaction with Signaling Pathways

• Snf1/AMPK Regulation: Snf1 phosphorylates PFK27 to modulate carbon utilization under glucose-limited conditions .

• Ras Activation: PFK27-mediated F2,6BP synthesis indirectly influences Ras signaling via Cdc25 interaction .

Transcriptional Regulation

• PFK27 expression is repressed by Rds2 under ethanol growth conditions, linking gluconeogenesis to glycolytic control .

Technical Considerations for Phosphofructokinase Antibodies

• Cross-Reactivity: Anti-PFKP antibodies (e.g., #5412) detect an ~80 kDa band in human, mouse, and rat tissues .

• Validation: Western blotting using tissue lysates (e.g., heart) confirms specificity .

• Storage: Lyophilized antibodies require reconstitution in sterile PBS and storage at -20°C .

Clinical and Therapeutic Implications

While PFK27 itself is yeast-specific, its mammalian counterparts (e.g., PFKFB3) are oncology targets:

• PFKFB3 Inhibition: Reduces glycolytic flux in NSCLC cells, sensitizing them to EGFR inhibitors .

• PFKP in Cancer: Promotes β-catenin nuclear translocation, driving aerobic glycolysis in glioblastoma .

Research Gaps and Future Directions

• Antibody Development: No PFK27-specific antibodies are yet reported; yeast studies rely on genetic knockouts .

• Mechanistic Studies: Structural analysis of PFK27’s ATP-binding domain could inform inhibitor design .